Pharmala Biotech Holdings Inc. (MDXXF)
| Market Cap | 9.67M |
| Revenue | n/a |
| Net Income | n/a |
| Shares Out | n/a |
| EPS | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 19,350 |
| Open | 0.1030 |
| Previous Close | 0.1030 |
| Day's Range | 0.1030 - 0.1030 |
| 52-Week Range | 0.0401 - 0.2563 |
| Beta | n/a |
| RSI | 41.58 |
| Earnings Date | n/a |
About Pharmala Biotech Holdings
Pharmala Biotech Holdings Inc., doing business as PharmAla, engages in the manufacture and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredient under the LaNeo brand name. The company is headquartered in Vancouver, Canada. [Read more]
News
PharmAla Issues Q2 Financial Statements
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and man...
PharmAla Contracts with Partner to Act as US Distributor
PharmAla sidesteps tariff risk and expands clinical operations in the United States by contracting with Sharp Clinical Services as distribution partner
PharmAla Completes Shipment of LaNeo™ MDMA to the University of Washington
TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Completes Shipment of LaNeo™ MDMA to UCLA for Schizophrenia Study
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla to supply STRONG STAR at UT Health San Antonio, with novel dosage form of LaNeo™ MDMA
TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla Signs Advisory Agreement with Mr. Matthew Azrieli
TORONTO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Issues Q1 Financial Statements
TORONTO, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla To Supply Merhavim Mental Health Centre Clinical Trial in Exchange for Full Data License, in Partnership with MAPS Israel
TORONTO, Jan. 20, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Announces Private Placement
TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
TORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla to supply LaNeo MDMA for Clinical Trial at Yale
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
TORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla to supply Harvard Medical School's Maclean Hospital with LaNeo MDMA
TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla to supply Johns Hopkins Medicine for Clinical Trial
TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manu...
PharmAla Launches MDMA Clinical Trial Tool for Researchers
TORONTO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manuf...
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
Red Light Holland Announces Completion of Full Psilocybin Extraction Report with PharmAla
Toronto, Ontario--(Newsfile Corp. - June 7, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth, and sale of functi...
Red Light Holland Completes First Phase of Natural Psilocybin Extraction with PharmAla, Initiates Optimization Process
Toronto, Ontario--(Newsfile Corp. - May 27, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth, and sale of functi...
PharmAla Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy
TORONTO, May 03, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufa...
Red Light Holland Initiates Psilocybin Extraction Phase with PharmAla Following Successful Testing and Preparation by CCrest Labs
Toronto, Ontario--(Newsfile Corp. - April 23, 2024) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland"), a company engaged in the production, growth and sale of funct...
PharmAla Closes Private Placement and Concurrent Debt Settlement
VANCOUVER, British Columbia, April 19, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, ...